A potential vaccine is being welcomed by HIV prevention advocates with ‘cautious optimism’
A vaccine targeting multiple strains of HIV is going into late-stage testing in the US and Europe later this year, but HIV experts have expressed ‘optimistic caution.’
Pharmaceutical giant Johnson & Johnson (J&J) is gearing up to test a new type of vaccine against HIV, according to Bloomberg.
Although, some HIV prevention advocates have highlighted the continued importance of current treatments – PrEP and condoms – in the road to ending HIV.
What does the trial involve?
The Mosaico study will see more than 3,800 men who have sex with men given a series of injections that the company hope will stop people from acquiring HIV.
Participants will receive six shots over four sessions, Anthony Fauci, the director of the US National Institute of Allergy and Infectious Diseases, told Bloomberg.